Page 2 - Katrin Dubischar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

If approved, VLA1553 could become the first licensed chikungunya vaccine available to address this unmet medical need.

NEW DELHI — A single-dose vaccine for chikungunya was found safe and produced a strong immune response against the viral disease, according to the results of the first phase 3 trial of the preventive published in The Lancet journal. However, the researchers were unable to investigate whether the VLA1553 vaccine, developed by French biotech company Valneva, protects against subsequent disease since the study was not conducted in regions where chikungunya is endemic. Chikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV), which is endemic in some regions of Africa, Asi...

"This could be the first chikungunya vaccine available for people living in endemic regions, as well as for travellers to endemic areas or areas at risk for an upcoming outbreak," said study lead author, Martina Schneider, Clinical Strategy Manager at Valneva.

A single-dose vaccine for chikungunya was found safe and produced a strong immune response against the viral disease, according to the first phase 3 trial of the preventive published in The Lancet journal.

Saint-Herblain (France), October 10, 2022 – Valneva SE VALNVLA, a specialty vaccine company, announces today it will present on its single-shot chikungunya